Cytek Biosciences (CTKB) EBITDA Margin (2020 - 2026)
Cytek Biosciences (CTKB) reported EBITDA Margin of 42.46% for Q1 2026, down 1345.0% on a YoY basis from 3.41% in Q1 2025, and up 38.15% quarter-over-quarter from 68.64% in Q4 2025.
Cytek Biosciences (CTKB) EBITDA Margin (2020 - 2026) Analysis & Trends
Cytek Biosciences has reported EBITDA Margin for 7 years, with the latest figure at 42.46% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 1345.0% year-over-year to 42.46%; the trailing twelve-month figure through Mar 2026 stood at 34.79% (down 2956.0% YoY), and the FY2025 full-year result was 31.92%, down 2956.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 42.46%, up from 68.64% in the prior quarter.
- The five-year high for EBITDA Margin was 16.63% in Q4 2024, with the low at 68.64% in Q4 2025.
- Historically, EBITDA Margin has averaged 12.15% across 5 years, with a median of 10.99% in 2025.
- Annual changes were most pronounced in 2024 — EBITDA Margin jumped 1548 bps — and 2025, when it slumped 8527 bps.
- Cytek Biosciences' EBITDA Margin stood at 7.35% in 2022, then jumped by 36 bps to 9.97% in 2023, then jumped by 67 bps to 16.63% in 2024, then tumbled by 513 bps to 68.64% in 2025, then surged by 38 bps to 42.46% in 2026.
- The last three EBITDA Margin figures came in at 42.46% (Q1 2026), 68.64% (Q4 2025), and 8.83% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.94% |
| 10 | Cytek Biosciences | - | - | 21.25 Mn | -42.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.46% |
| Dec 31, 2025 | -68.64% |
| Sep 30, 2025 | -8.83% |
| Jun 30, 2025 | -10.99% |
| Mar 31, 2025 | -29.01% |
| Dec 31, 2024 | 16.63% |
| Sep 30, 2024 | 2.40% |
| Jun 30, 2024 | -19.47% |
| Mar 31, 2024 | -14.37% |
| Dec 31, 2023 | 9.97% |
| Sep 30, 2023 | -13.08% |
| Jun 30, 2023 | -11.19% |
| Mar 31, 2023 | -18.06% |
| Dec 31, 2022 | 7.35% |
| Sep 30, 2022 | 2.14% |
| Jun 30, 2022 | -2.22% |
| Mar 31, 2022 | -6.72% |
| Dec 31, 2021 | -1.52% |
| Sep 30, 2021 | 8.43% |
| Jun 30, 2021 | 9.67% |